GENinCode has reported interim results for the 6 months to June 2025, aligned with the August trading update. Revenues grew 15% in the period to £1.6m and gross margin remained strong at 53%. GENinCode has reported an EBITDA loss, adjusted for SBP and non-cash foreign exchange effects, of £2.1m, in line with 1H24, demonstrating the company’s on-going tight costs control. Operationally, GENinCode is now selling tests to 40 US institutions, progressing pilot programmes in Spain, growing its collab ....
